Should I pile into Motif Bio plc, up 35% today?

Successful Phase 3 trials at Motif Bio plc (LON: MTFB) could signal good times ahead.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Good news hit the wires this morning from Motif Bio (LSE: MTFB), a clinical-stage biopharmaceutical company aiming to develop novel antibiotics. The market likes it and the shares are around 36% higher as I write.

The excitement surrounds details of a positive topline result from a global Phase 3 clinical trial called REVIVE-2, which is focused on the firm’s investigational drug candidate iclaprim for patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI). 

A new drug is born

Chief executive Graham Lumsden tells us that today’s positive results mean the company has completed the two required Phase 3 trials in ABSSSI necessary to submit a new drug application to the US Food and Drug Administration (FDA), which Motif Bio plans to do by the end of the first quarter of 2018.

According to medical experts, ABSSSI is a serious infection and every year around 3.6m people in the US are hospitalised with it for several days. The problem with existing treatments is that they tend to be toxic to the kidneys and that’s bad because around 26% of those suffering with ABSSSI also have kidney disease. Happily, during the trial, kidney toxicity was not observed with iclaprim.

The hope now is that Iclaprim may prove to be “an important option for the growing population of patients with ABSSSI and kidney disease who need a safe and effective antibiotic targeting Gram-positive bacteria, including MRSA.” Meanwhile, from an investing point of view, the outcome of the trial means that Iclaprim now has value, which Motif Bio may be able to commercialise down the road.

Will the cash roll in?

Perhaps Iclaprim will go on to become a blockbusting best-seller. If so, it could end up delivering much-needed incoming cash flow to the company’s coffers. We saw with the recent interim results that Motif Bio has no income and spent more than $28m on operations during the first half of the year – early-stage drug development is an expensive activity. Investors are keeping the firm solvent, and a placing in June brought in just under $24m. But even then, the cash sitting on the balance sheet was only around $29m and the cash-burning agenda for operations marches on.

Of course, Motif Bio isn’t the only drug-development company with precarious finances, and we investors have to make judgements in such cases that balance the financial risks of owning the shares against the upside potential in a firm’s story. One consequence of this push-pull scenario in Motif Bio’s case is that the share price seems to fly up and down on news announcements depending on their tone. So, although the long-term story is full of potential, maybe it’s best to buy-in on down days rather than up days like today.  

The news today takes it closer to earning income, but the firm’s market capitalisation running close to £129m strikes me as hefty for a company with everything yet to prove. This stock could be a millionaire-maker or it could, yet, send you to the poorhouse, so I remain cautious.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in Motif Bio. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »